Status:
COMPLETED
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Lead Sponsor:
Boehringer Ingelheim
Conditions:
HIV Infections
Eligibility:
All Genders
18-64 years
Brief Summary
This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients. Data will only ...
Detailed Description
Study Design: non-interventional uncontrolled observational study
Eligibility Criteria
Inclusion
- Inclusion criteria:
- HIV-1 infected male and female 18 years and above;
- anti-retroviral therapy (ART) naive and pre-treated patients switching from a nevirapine immediate release or other ART.
- Exclusion criteria:
- Consistent with the current VIRAMUNE prolonged release SPC.
Exclusion
Key Trial Info
Start Date :
March 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
398 Patients enrolled
Trial Details
Trial ID
NCT01524900
Start Date
March 1 2012
End Date
May 1 2014
Last Update
June 2 2015
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 6
Graz, Austria
2
Boehringer Ingelheim Investigational Site 5
Salzburg, Austria
3
Boehringer Ingelheim Investigational Site 1
Vienna, Austria
4
Boehringer Ingelheim Investigational Site 2
Vienna, Austria